Neuregulin-1β for the treatment of systolic heart failure

Journal of Molecular and Cellular Cardiology

Volumn 51, Issue 4, 2011, Pages 501-505

  Sawyer, Douglas B ^a,b   Caggiano, Anthony ^a,b  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ACORDA THERAPEUTICS INC   (United States)

Author keywords

Cardiac myocyte; ErbB2; ErbB4; Glial growth factor 2; Heregulin

Indexed keywords

CALCIUM; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 4; GLYCOSYLATED RECOMBINANT HUMAN NEUREGULIN 1BETA3; NEU DIFFERENTIATION FACTOR; NEUREGULIN 1BETA; RECOMBINANT NEUREGULIN 1BETA; UNCLASSIFIED DRUG;

CALCIUM TRANSPORT; GENE; GENE EXPRESSION; GENE FUNCTION; HEART DEVELOPMENT; HEART FAILURE; HEART FUNCTION; HEART MUSCLE CELL; HEART MUSCLE CONTRACTILITY; HEART VENTRICLE; HUMAN; MICROVASCULAR ENDOTHELIAL CELL; NAUSEA; NEUREGULIN 1 GENE; NONHUMAN; PARACRINE SIGNALING; PRIORITY JOURNAL; PROTEIN FAMILY; REVIEW; SYSTOLIC HEART FAILURE; TRANSLATIONAL RESEARCH; VENTRICULAR TRABECULATION;

ANIMALS; CLINICAL TRIALS AS TOPIC; DRUG EVALUATION, PRECLINICAL; HEART FAILURE, SYSTOLIC; HUMANS; NEUREGULIN-1; ORGAN SPECIFICITY; PARACRINE COMMUNICATION; RECOMBINANT PROTEINS;

ANIMALIA; MUS;

EID: 80052807325     PISSN: 00222828     EISSN: 10958584     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2011.06.016     Document Type: Review

References (69)

1. Jose V.J., Zechariah T.U., George P., Jonathan V. Growth hormone therapy in patients with dilated cardiomyopathy: preliminary observations of a pilot study. Indian Heart J Mar-Apr 1999, 51(2):183-185.
2. Acevedo M., Corbalan R., Chamorro G., Jalil J., Nazzal C., Campusano C., et al. Administration of growth hormone to patients with advanced cardiac heart failure: effects upon left ventricular function, exercise capacity, and neurohormonal status. Int J Cardiol 2003, 87(2-3):185-191.
3. Cittadini A., Stromer H., Katz S.E., Clark R., Moses A.C., Morgan J.P., et al. Differential cardiac effects of growth hormone and insulin-like growth factor-1 in the rat. A combined in vivo and in vitro evaluation. Circulation 1996, 93(4):800-809.
4. Falls D.L. Neuregulins: functions, forms, and signaling strategies. Exp Cell Res 2003, 284(1):14-30.
5. Gassmann M., Casagranda F., Orioli D., Simon H., Lai C., Klein R., et al. Aberrant neural and cardiac development in mice lacking the ErbB4 neuregulin receptor [see comments]. Nature 1995, 378(6555):390-394.
6. Lee A.D., Hansen P.A., Holloszy J.O. Wortmannin inhibits insulin-stimulated but not contraction-stimulated glucose transport activity in skeletal muscle. FEBS Lett 1995, 361(1):51-54.
7. Meyer D., Birchmeier C. Multiple essential functions of neuregulin in development. Nature 1995, 378(6555):386-390.
8. Liu X., Hwang H., Cao L., Buckland M., Cunningham A., Chen J., et al. Domain-specific gene disruption reveals critical regulation of neuregulin signaling by its cytoplasmic tail. Proc Natl Acad Sci USA 1998, 95(22):13024-13029.
9. Lee K.F., Simon H., Chen H., Bates B., Hung M.C., Hauser C. Requirement for neuregulin receptor erbB2 in neural and cardiac development. Nature 1995, 378(6555):394-398.
10. Zhao Y.Y., Sawyer D.R., Baliga R.R., Opel D.J., Han X., Marchionni M.A., et al. Neuregulins promote survival and growth of cardiac myocytes. Persistence of ErbB2 and ErbB4 expression in neonatal and adult ventricular myocytes. J Biol Chem 1998, 273(17):10261-10269.
11. Cote G.M., Miller T.A., Lebrasseur N.K., Kuramochi Y., Sawyer D.B. Neuregulin-1alpha and beta isoform expression in cardiac microvascular endothelial cells and function in cardiac myocytes in vitro. Exp Cell Res 2005, 311(1):135-146.
12. Lemmens K., Doggen K., De Keulenaer G.W. Activation of the neuregulin/ErbB system during physiological ventricular remodeling in pregnancy. Am J Physiol Heart Circ Physiol 2011, 300(3):H931-H942.
13. Kuramochi Y., Cote G.M., Guo X., LeBrasseur N.K., Cui L., Liao R., et al. Cardiac endothelial cells regulate ROS-induced cardiomyocyte apoptosis through neuregulin-1beta /erbB4 signaling. J Biol Chem 2004, 279(49):51141-51147.
14. Russell K.S., Stern D.F., Polverini P.J., Bender J.R. Neuregulin activation of ErbB receptors in vascular endothelium leads to angiogenesis. Am J Physiol Heart Circ Physiol 1999, 277(6 Pt 2):H2205-H2211.
15. Slamon D.J., Leyland-Jones B., Shak S., Fuchs H., Paton V., Bajamonde A., et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001, 344(11):783-792.
16. Ozcelik C., Erdmann B., Pilz B., Wettschureck N., Britsch S., Hubner N., et al. Conditional mutation of the ErbB2 (HER2) receptor in cardiomyocytes leads to dilated cardiomyopathy. Proc Natl Acad Sci USA 2002, 99(13):8880-8885.
17. Crone S.A., Zhao Y.Y., Fan L., Gu Y., Minamisawa S., Liu Y., et al. ErbB2 is essential in the prevention of dilated cardiomyopathy. Nat Med 2002, 8(5):459-465.
18. Liu F.F., Stone J.R., Schuldt A.J., Okoshi K., Okoshi M.P., Nakayama M., et al. Heterozygous knockout of neuregulin-1 gene in mice exacerbates doxorubicin-induced heart failure. Am J Physiol Heart Circ Physiol 2005, 289(2):H660-H666.
19. Sawyer D.B., Zuppinger C., Miller T.A., Eppenberger H.M., Suter T.M. Modulation of anthracycline-induced myofibrillar disarray in rat ventricular myocytes by neuregulin-1beta and anti-erbB2: potential mechanism for trastuzumab-induced cardiotoxicity. Circulation 2002, 105(13):1551-1554.
20. Moondra V., Sarma S., Buxton T., Safa R., Cote G., Storer T., et al. Serum Neuregulin-1? as a Biomarker of Cardiovascular Fitness. Open Biomark J 2009, 2:5.
21. Lebrasseur N.K., Cote G.M., Miller T.A., Fielding R.A., Sawyer D.B. Regulation of neuregulin/ErbB signaling by contractile activity in skeletal muscle. Am J Physiol Cell Physiol 2003, 284(5):C1149-C1155.
22. Ky B., Kimmel S.E., Safa R.N., Putt M.E., Sweitzer N.K., Fang J.C., et al. Neuregulin-1 beta is associated with disease severity and adverse outcomes in chronic heart failure. Circulation 2009, 120(4):310-317.
23. Kuramochi Y., Cote G.M., Guo X., Lebrasseur N.K., Cui L., Liao R., et al. Cardiac endothelial cells regulate reactive oxygen species-induced cardiomyocyte apoptosis through neuregulin-1beta/erbB4 signaling. J Biol Chem 2004, 279(49):51141-51147.
24. Lemmens K., Doggen K., De Keulenaer G.W. Role of neuregulin-1/ErbB signaling in cardiovascular physiology and disease: implications for therapy of heart failure. Circulation 2007, 116(8):954-960.
25. Doggen K., Ray L., Mathieu M., Mc Entee K., Lemmens K., De Keulenaer G.W. Ventricular ErbB2/ErbB4 activation and downstream signaling in pacing-induced heart failure. J Mol Cell Cardiol 2009, 46(1):33-38.
26. Rohrbach S., Yan X., Weinberg E.O., Hasan F., Bartunek J., Marchionni M.A., et al. Neuregulin in cardiac hypertrophy in rats with aortic stenosis. Differential expression of erbB2 and erbB4 receptors. Circulation 1999, 100(4):407-412.
27. Rohrbach S., Niemann B., Silber R.E., Holtz J. Neuregulin receptors erbB2 and erbB4 in failing human myocardium - depressed expression and attenuated activation. Basic Res Cardiol 2005, 100(3):240-249.
28. Xu G., Watanabe T., Iso Y., Koba S., Sakai T., Nagashima M., et al. Preventive effects of heregulin-beta1 on macrophage foam cell formation and atherosclerosis. Circ Res 2009, 105(5):500-510.
29. Hintsanen M., Elovainio M., Puttonen S., Kivimaki M., Raitakari O.T., Lehtimaki T., et al. Neuregulin-1 genotype moderates the association between job strain and early atherosclerosis in young men. Ann Behav Med 2007, 33(2):148-155.
30. Liu X., Gu X., Li Z., Li X., Li H., Chang J., et al. Neuregulin-1/erbB-activation improves cardiac function and survival in models of ischemic, dilated, and viral cardiomyopathy. J Am Coll Cardiol 2006, 48(7):1438-1447.
31. Bian Y., Sun M., Silver M., Ho K.K., Marchionni M.A., Caggiano A.O., et al. Neuregulin-1 attenuated doxorubicin-induced decrease in cardiac troponins. Am J Physiol Heart Circ Physiol 2009, 297(6):H1974-H1983.
32. Li J., Gu X.H., Duan J.C., Zeng L., Li Y., Wang L. Effects of recombined human neuregulin on the contractibility of cardiac muscles of rhesus monkeys with pacing-induced heart failure. Sichuan Da Xue Xue Bao Yi Xue Ban 2007, 38(1):105-108.
33. Bersell K., Arab S., Haring B., Kuhn B. Neuregulin1/ErbB4 signaling induces cardiomyocyte proliferation and repair of heart injury. Cell 2009, 138(2):257-270.
34. Ganguly A., iaci J.F., Srinivas M., Vecchione A.V., Hackett C.S., Kasperbauer S., et al. Neuregulin Treatment of Heart Failure in Rat. Circ Res 2008, 103:e51. [2008; 103: e51].
35. Kramer R., Bucay N., Kane D.J., Martin L.E., Tarpley J.E., Theill L.E. Neuregulins with an Ig-like domain are essential for mouse myocardial and neuronal development. Proc Natl Acad Sci USA 1996, 93(10):4833-4838.
36. Eto K., Eda K., Kanemoto S., Abe S. The immunoglobulin-like domain is involved in interaction of Neuregulin1 with ErbB. Biochem Biophys Res Commun 2006, 350(2):263-271.
37. Lemmens K., Fransen P., Sys S.U., Brutsaert D.L., De Keulenaer G.W. Neuregulin-1 induces a negative inotropic effect in cardiac muscle: role of nitric oxide synthase. Circulation 2004, 109(3):324-326.
38. Okoshi K., Nakayama M., Yan X., Okoshi M.P., Schuldt A.J., Marchionni M.A., et al. Neuregulins regulate cardiac parasympathetic activity: muscarinic modulation of beta-adrenergic activity in myocytes from mice with neuregulin-1 gene deletion. Circulation 2004, 110(6):713-717.
39. Timolati F., Ott D., Pentassuglia L., Giraud M.N., Perriard J.C., Suter T.M., et al. Neuregulin-1 beta attenuates doxorubicin-induced alterations of excitation-contraction coupling and reduces oxidative stress in adult rat cardiomyocytes. J Mol Cell Cardiol 2006, 41(5):845-854.
40. Brero A., Ramella R., Fitou A., Dati C., Alloatti G., Gallo M.P., et al. Neuregulin-1beta1 rapidly modulates nitric oxide synthesis and calcium handling in rat cardiomyocytes. Cardiovasc Res 2010, 88(3):443-452.
41. Gao R., Zhang J., Cheng L., Wu X., Dong W., Yang X., et al. A Phase II, randomized, double-blind, multicenter, based on standard therapy, placebo-controlled study of the efficacy and safety of recombinant human neuregulin-1 in patients with chronic heart failure. J Am Coll Cardiol 2010, 55(18):1907-1914.
42. Jabbour A., Hayward C.S., Keogh A.M., Kotlyar E., McCrohon J.A., England J.F., et al. Parenteral administration of recombinant human neuregulin-1 to patients with stable chronic heart failure produces favourable acute and chronic haemodynamic responses. Eur J Heart Fail 2011, 13(1):83-92.
43. Zensun Sci., &, Tech.Co.L. Clinical Trial to Evaluate the Efficacy and Safety of Recombinant Human Neuregulin-1 for Subcutaneous Administration in Patients With Chronic Systolic Heart Failure. Clinical Trials Gov 2010.
44. Zensun Sci., &, Tech.Co.L. Study of the Survival of Recombinant Human Neuregulin-1? in Chronic Heart Failure (CHF) Patients. Clinical Trials Gov 2010.
45. Zensun Sci., &, Tech.Co.L. Efficacy and Safety of Human Neuregulin-1 to Treat Stable Chronic Heart Failure (ZS-01-210). Clinical Trials Gov 2010.
46. Therapeutics A. Single Ascending Doses of GGF2 in Patients With Left Ventricular Dysfunction and Symptomatic Heart Failure (GGF2-1101-1). Clinical Trials Gov 2010.
47. Yarden Y., Sliwkowski M.X. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001, 2(2):127-137.
48. Chua Y.L., Ito Y., Pole J.C., Newman S., Chin S.F., Stein R.C., et al. The NRG1 gene is frequently silenced by methylation in breast cancers and is a strong candidate for the 8p tumour suppressor gene. Oncogene 2009, 28(46):4041-4052.
49. Atlas E., Cardillo M., Mehmi I., Zahedkargaran H., Tang C., Lupu R. Heregulin is sufficient for the promotion of tumorigenicity and metastasis of breast cancer cells in vivo. Mol Cancer Res 2003, 1(3):165-175.
50. Kato T., Kasai A., Mizuno M., Fengyi L., Shintani N., Maeda S., et al. Phenotypic characterization of transgenic mice overexpressing neuregulin-1. PLoS One 2010, 5(12):e14185.
51. Marchionni M.A., Cannella B., Hoban C., Gao Y.L., Garcia-Arenas R., Lawson D., et al. Neuregulin in neuron/glial interactions in the central nervous system. GGF2 diminishes autoimmune demyelination, promotes oligodendrocyte progenitor expansion, and enhances remyelination. Adv Exp Med Biol 1999, 468:283-295.
52. Xu Z., Jiang J., Ford G., Ford B.D. Neuregulin-1 is neuroprotective and attenuates inflammatory responses induced by ischemic stroke. Biochem Biophys Res Commun 2004, 322(2):440-446.
53. Iaci J.F., Ganguly A., Finklestein S.P., Parry T.J., Ren J., Saha S., et al. Glial growth factor 2 promotes functional recovery with treatment initiated up to 7days after permanent focal ischemic stroke. Neuropharmacology 2010, 59(7-8):640-649.
54. Stefansson H., Sigurdsson E., Steinthorsdottir V., Bjornsdottir S., Sigmundsson T., Ghosh S., et al. Neuregulin 1 and susceptibility to schizophrenia. Am J Hum Genet 2002, 71(4):877-892.
55. Moises H.W., Zoega T., Gottesman I.I. The glial growth factors deficiency and synaptic destabilization hypothesis of schizophrenia. BMC Psychiatry 2002, 2:8.
56. Cai J., Peng X., Nelson K.D., Eberhart R., Smith G.M. Synergistic improvements in cell and axonal migration across sciatic nerve lesion gaps using bioresorbable filaments and heregulin-beta1. J Biomed Mater Res A 2004, 69(2):247-258.
57. ter Laak M.P., Hamers F.P., Kirk C.J., Gispen W.H. rhGGF2 protects against cisplatin-induced neuropathy in the rat. J Neurosci Res 2000, 60(2):237-244.
58. Jo S.A., Zhu X., Marchionni M.A., Burden S.J. Neuregulins are concentrated at nerve-muscle synapses and activate ACh- receptor gene expression. Nature 1995, 373(6510):158-161.
59. Ford B.D., Han B., Fischbach G.D. Differentiation-dependent regulation of skeletal myogenesis by neuregulin-1. Biochem Biophys Res Commun 2003, 306(1):276-281.
60. Suarez E., Bach D., Cadefau J., Palacin M., Zorzano A., Guma A. A novel role of neuregulin in skeletal muscle. Neuregulin stimulates glucose uptake, glucose transporter translocation, and transporter expression in muscle cells. J Biol Chem 2001, 276(21):18257-18264.
61. Florini J.R., Samuel D.S., Ewton D.Z., Kirk C., Sklar R.M. Stimulation of myogenic differentiation by a neuregulin, glial growth factor 2. Are neuregulins the long-sought muscle trophic factors secreted by nerves?. J Biol Chem 1996, 271(22):12699-12702.
62. Zorzano A., Kaliman P., Guma A., Palacin M. Intracellular signals involved in the effects of insulin-like growth factors and neuregulins on myofibre formation. Cell Signal 2003, 15(2):141-149.
63. Fukazawa R., Miller T.A., Kuramochi Y., Frantz S., Kim Y.D., Marchionni M.A., et al. Neuregulin-1 protects ventricular myocytes from anthracycline-induced apoptosis via erbB4-dependent activation of PI3-kinase/Akt. J Mol Cell Cardiol 2003, 35(12):1473-1479.
64. Grazette L.P., Boecker W., Matsui T., Semigran M., Force T.L., Hajjar R.J., et al. Inhibition of ErbB2 causes mitochondrial dysfunction in cardiomyocytes: implications for herceptin-induced cardiomyopathy. J Am Coll Cardiol 2004, 44(11):2231-2238.
65. Baliga R.R., Pimental D.R., Zhao Y.Y., Simmons W.W., Marchionni M.A., Sawyer D.B., et al. NRG-1-induced cardiomyocyte hypertrophy. Role of PI-3-kinase, p70(S6K), and MEK-MAPK-RSK. Am J Physiol Heart Circ Physiol 1999, 277(5 Pt 2):H2026-H37.
66. Kuramochi Y., Guo X., Sawyer D.B. Neuregulin activates erbB2-dependent src/FAK signaling and cytoskeletal remodeling in isolated adult rat cardiac myocytes. J Mol Cell Cardiol 2006, 41(2):228-235.
67. Zhu W.Z., Xie Y., Moyes K.W., Gold J.D., Askari B., Laflamme M.A. Neuregulin/ErbB signaling regulates cardiac subtype specification in differentiating human embryonic stem cells. Circ Res 2010, 107(6):776-786.
68. Rentschler S., Zander J., Meyers K., France D., Levine R., Porter G., et al. Neuregulin-1 promotes formation of the murine cardiac conduction system. Proc Natl Acad Sci USA 2002, 99(16):10464-10469.
69. Safa R., Peng X.Y., Pentassuglia L., Lim C.C., Lamparter M., Silverstein C., et al. Neuregulin-1{beta} Regulation of Embryonic Endothelial Progenitor Cell Survival. Am J Physiol Heart Circ Physiol 2011, 300(46):H1311-H1319.